C. Wagner

Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD‐subgroup analyses across four randomized trials

W. Sandborn, G. Lichtenstein, A. Olson, 2009, Alimentary pharmacology & therapeutics.

Molecular impact of MinK on the enantiospecific block of IKs by chromanols

B Attali, B. Attali, U. Gerlach, 2000, British journal of pharmacology.